BNF:

7.4.5

Status:

Grey - after consultant/specialist initiation

Decision Date:

September 2014

Comments

As per SLS criteria, usually 2nd line to a PDE type 5 inhibitor

Grey Drug Classifications

• 5: Less cost-effective than current standard therapy

search again